Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC50 of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.
Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.
Peb muaj ntau lub Hoobkas zoo nrog kev koom tes sib sib zog nqus, uas tuaj yeem muab koj cov khoom zoo thiab cov nqi sib tw. Thiab peb tseem tuaj yeem muab cov luv nqi rau kev yuav khoom ntau.Thiab peb koom tes nrog ntau lub tuam txhab xa khoom xa tuaj, tuaj yeem xa cov khoom lag luam kom nyab xeeb thiab ntseeg nkaws rau koj txhais tes. Lub sij hawm xa tuaj yog li 3-20 hnub tom qab tau txais kev pom zoo ntawm kev them nyiaj.
Product Name: | Udenafil |
Synonyms: | 5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;Zydena;Udenafil(DA 8159,Zydena);BenzenesulfonaMide,3-(6,7-dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;Udenafil, DA 8159;CS-1353;Udenafil, >=98% |
CAS: | 268203-93-6 |
MF: | C25H36N6O4S |
MW: | 516.66 |
EINECS: | 251-228-4 |
Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals |
Mol File: | 268203-93-6.mol |
![]() |
Udenafil Chemical Properties |
Melting point | 152-159°C |
Boiling point | 697.0±65.0 °C(Predicted) |
ceev | 1.35 |
cia temp. | under inert gas (nitrogen or Argon) at 2-8°C |
solubility | Chloroform (Slightly), Methanol (Sparingly) |
daim ntawv | Solid |
pka | 11.07±0.50(Predicted) |
xim | White to Pale Beige |
1. Koj puas yog lub Hoobkas lossis tuam txhab lag luam?
Peb yog ib qho kev sib koom ua ke kev lag luam thiab kev lag luam, muab kev pabcuam ib-nres.OEM tuaj yeem txais.
2. Koj puas muab cov qauv? Puas yog dawb lossis ntxiv?
Cov qauv dawb.Cov qauv tus nqi thauj khoom yuav tsum tau them los ntawm koj sab.
3. Koj puas muaj daim ntawv pov thawj ntsig txog kev tswj xyuas zoo?
ISO 9001: 2008 ntawv pov thawj los xyuas kom meej qhov zoo.
4. Kuv yuav muab dab tsi kom tau txais cov lus hais?
Pls qhia peb txog cov khoom lag luam uas koj xav tau, xaj kom muaj nuj nqis, chaw nyob thiab cov kev xav tau tshwj xeeb.Cov lus hais yuav ua rau koj siv sijhawm.
5. Hom kev them nqi twg koj nyiam? Cov nqe lus twg raug lees txais?
Txais Cov Lus Cog Tseg: FOB, CFR, CIF, EXW;
Txais Nyiaj Them Nqi: USD;
Hom Kev Them Nyiaj: T / T, Western Union; Paypal, Trade Assurance.
Lus Hais: Lus Askiv.
Cov khoom qeb